Treat-to-Target Outcomes and Measures of Treatment Success in Three Phase 3 Trials of Tapinarof Cream 1% Once Daily for Mild to Severe Plaque Psoriasis. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 6, n. 6, p. s52, 2022. DOI: 10.25251/skin.6.supp.52. Disponível em: https://skin.dermsquared.com/skin/article/view/1807. Acesso em: 18 apr. 2026.